Pharma Major Lupin

The governmental commission on monitoring foreign investment has approved the buyout of the Russian Biocom (CIA International) by an Indian pharmaceutical company, head of the Federal Anti-Monopoly Service Igor Artemyev said after the commission’s meeting. Lupin will invest USD 200m into Biocom.

“India’s Lupin will buy out 100% shares in Biocom for USD Biocom is the manufacturer of 17 items on the life-saving drugs list,” he added. “The investment which the Indian company expects to inject in line with the business plan in the near term amount to USD 200m,” Artemyev added.

10 December 2015
rns.online

Indian pharmaceutical manufacturer Pharma Major Lupin intends to purchase the Biocom plant in Stavropol, Lupin said in a statement. The amount of the potential transaction has not been disclosed.

“The acquisition marks Lupin’s foray into the Russian pharmaceutical market which recorded RUB 765 billion in sales, placing it as one of the Top 10 pharmaceutical markets in the world in 2014,” the press release says.

Biocom had turnover of RUB 861.2 million in 2014, according to Lupin.

“We are excited about our entry into the Russian market through Biocom. Russia is an attractive market and this acquisition will also enable our expansion into neighboring markets as well as other Eastern European markets in the future,” Lupin Limited CEO Vinita Gupta commented.
 

01 July 2015
ITAR-TASS
Investor
Stavropol region

Investor profile

Pharma Major Lupin

India

Company's website: https://lupin.com

T: +91 22 6640 2222

Public company

E-mail: secretarial@lupin.com

Contact: Dr. Desh Bandhu Gupta, Founder and Chairman of the Board of Directors

Lupin Pharmaceuticals Inc is India’s fourth biggest pharmaceutical company by sales volume. Lupin specializes in the production of generic and brand drugs as well as active pharmaceutical substations. The company was established in 1968 and its products are present in more than 100 countries. Revenue totalled USD 1.8 billion in the 2013—2014 financial year, while net profit amounted to USD 299.9 million. Lupin ranks fifth among generics manufacturers in the U.S. and is the third largest pharmaceutical manufacturer in India in terms of revenue.